Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Circ Res ; 89(11): 997-1004, 2001 Nov 23.
Article in English | MEDLINE | ID: mdl-11717156

ABSTRACT

beta-Adrenergic receptor (betaAR) signaling, which elevates intracellular cAMP and enhances cardiac contractility, is severely impaired in the failing heart. Protein kinase A (PKA) is activated by cAMP, but the long-term physiological effect of PKA activation on cardiac function is unclear. To investigate the consequences of chronic cardiac PKA activation in the absence of upstream events associated with betaAR signaling, we generated transgenic mice that expressed the catalytic subunit of PKA in the heart. These mice developed dilated cardiomyopathy with reduced cardiac contractility, arrhythmias, and susceptibility to sudden death. As seen in human heart failure, these abnormalities correlated with PKA-mediated hyperphosphorylation of the cardiac ryanodine receptor/Ca(2+)-release channel, which enhances Ca(2+) release from the sarcoplasmic reticulum, and phospholamban, which regulates the sarcoplasmic reticulum Ca(2+)-ATPase. These findings demonstrate a specific role for PKA in the pathogenesis of heart failure, independent of more proximal events in betaAR signaling, and support the notion that PKA activity is involved in the adverse effects of chronic betaAR signaling.


Subject(s)
Cardiomyopathy, Dilated/etiology , Cyclic AMP-Dependent Protein Kinases/metabolism , Cyclic AMP-Dependent Protein Kinases/physiology , Death, Sudden, Cardiac/etiology , Animals , Calcium-Binding Proteins/metabolism , Cardiomyopathy, Dilated/enzymology , Cardiomyopathy, Dilated/metabolism , Cyclic AMP-Dependent Protein Kinases/genetics , Enzyme Activation , Humans , Mice , Mice, Transgenic , Myocardial Contraction , Myosin Heavy Chains/genetics , Phosphorylation , Ryanodine Receptor Calcium Release Channel/metabolism
2.
Proc Natl Acad Sci U S A ; 98(6): 3328-33, 2001 Mar 13.
Article in English | MEDLINE | ID: mdl-11248078

ABSTRACT

Signaling events controlled by calcineurin promote cardiac hypertrophy, but the degree to which such pathways are required to transduce the effects of various hypertrophic stimuli remains uncertain. In particular, the administration of immunosuppressive drugs that inhibit calcineurin has inconsistent effects in blocking cardiac hypertrophy in various animal models. As an alternative approach to inhibiting calcineurin in the hearts of intact animals, transgenic mice were engineered to overexpress a human cDNA encoding the calcineurin-binding protein, myocyte-enriched calcineurin-interacting protein-1 (hMCIP1) under control of the cardiac-specific, alpha-myosin heavy chain promoter (alpha-MHC). In unstressed mice, forced expression of hMCIP1 resulted in a 5-10% decline in cardiac mass relative to wild-type littermates, but otherwise produced no apparent structural or functional abnormalities. However, cardiac-specific expression of hMCIP1 inhibited cardiac hypertrophy, reinduction of fetal gene expression, and progression to dilated cardiomyopathy that otherwise result from expression of a constitutively active form of calcineurin. Expression of the hMCIP1 transgene also inhibited hypertrophic responses to beta-adrenergic receptor stimulation or exercise training. These results demonstrate that levels of hMCIP1 producing no apparent deleterious effects in cells of the normal heart are sufficient to inhibit several forms of cardiac hypertrophy, and suggest an important role for calcineurin signaling in diverse forms of cardiac hypertrophy. The future development of measures to increase expression or activity of MCIP proteins selectively within the heart may have clinical value for prevention of heart failure.


Subject(s)
Calcineurin Inhibitors , Cardiomyopathy, Dilated/prevention & control , Muscle Proteins/physiology , Animals , Cardiomyopathy, Dilated/genetics , Cardiomyopathy, Dilated/pathology , DNA-Binding Proteins , Female , Gene Expression , Humans , Intracellular Signaling Peptides and Proteins , Mice , Mice, Inbred C57BL , Mice, Transgenic , Models, Genetic , Muscle Proteins/genetics , Myosin Heavy Chains/genetics , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/physiology
3.
Dev Biol ; 217(2): 301-9, 2000 Jan 15.
Article in English | MEDLINE | ID: mdl-10625555

ABSTRACT

The zinc finger transcription factors GATA4, -5, and -6 and the homeodomain protein Nkx2.5 are expressed in the developing heart and have been shown to activate a variety of cardiac-specific genes. To begin to define the regulatory relationships between these cardiac transcription factors and to understand the mechanisms that control their expression during cardiogenesis, we analyzed the mouse GATA6 gene for regulatory elements sufficient to direct cardiac expression during embryogenesis. Using beta-galactosidase fusion constructs in transgenic mice, a 4.3-kb 5' regulatory region that directed transcription specifically in the cardiac lineage, beginning at the cardiac crescent stage, was identified. Thereafter, transgene expression became compartmentalized to the outflow tract, a portion of the right ventricle, and a limited region of the common atrial chamber of the embryonic heart. Further dissection of this regulatory region identified a 1.8-kb cardiac-specific enhancer that recapitulated the expression pattern of the larger region when fused to a heterologous promoter and a smaller 500-bp subregion that retained cardiac expression, but was quantitatively weaker. The GATA6 cardiac enhancer contained a binding site for Nkx2.5 that was essential for cardiac-specific expression in transgenic mice. These studies demonstrate that GATA6 is a direct target gene for Nkx2.5 in the developing heart and reveal a mutually reinforcing regulatory network of Nkx2.5 and GATA transcription factors during cardiogenesis.


Subject(s)
DNA-Binding Proteins/genetics , Enhancer Elements, Genetic , Gene Expression Regulation, Developmental , Heart/embryology , Homeodomain Proteins/metabolism , Transcription Factors/genetics , Xenopus Proteins , Animals , Base Sequence , Binding Sites , Cell Lineage , GATA6 Transcription Factor , Homeobox Protein Nkx-2.5 , Mice , Mice, Transgenic , Molecular Sequence Data , Promoter Regions, Genetic , Protein Binding , Transcriptional Activation
4.
Cell ; 93(2): 215-28, 1998 Apr 17.
Article in English | MEDLINE | ID: mdl-9568714

ABSTRACT

In response to numerous pathologic stimuli, the myocardium undergoes a hypertrophic response characterized by increased myocardial cell size and activation of fetal cardiac genes. We show that cardiac hypertrophy is induced by the calcium-dependent phosphatase calcineurin, which dephosphorylates the transcription factor NF-AT3, enabling it to translocate to the nucleus. NF-AT3 interacts with the cardiac zinc finger transcription factor GATA4, resulting in synergistic activation of cardiac transcription. Transgenic mice that express activated forms of calcineurin or NF-AT3 in the heart develop cardiac hypertrophy and heart failure that mimic human heart disease. Pharmacologic inhibition of calcineurin activity blocks hypertrophy in vivo and in vitro. These results define a novel hypertrophic signaling pathway and suggest pharmacologic approaches to prevent cardiac hypertrophy and heart failure.


Subject(s)
Calcineurin/physiology , Cardiomegaly/genetics , Myocardium/pathology , Nuclear Proteins , Signal Transduction/physiology , Transcriptional Activation/physiology , Angiotensin II/pharmacology , Animals , Animals, Newborn , Atrial Natriuretic Factor/genetics , Calcineurin/genetics , Cardiomegaly/enzymology , Cardiomegaly/prevention & control , Cell Nucleus/metabolism , DNA-Binding Proteins/metabolism , GATA4 Transcription Factor , Immunosuppressive Agents/pharmacology , Mice , Mice, Transgenic , Myocardium/metabolism , NFATC Transcription Factors , Natriuretic Peptide, Brain , Phenylephrine/pharmacology , Promoter Regions, Genetic/genetics , Rats , Recombinant Fusion Proteins , Transcription Factors/metabolism , Transcription, Genetic , Zinc Fingers
5.
Development ; 122(10): 3185-94, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8898231

ABSTRACT

We have produced null mutant mouse embryonic stem cells for the cell adhesion molecule E-cadherin. Such E-cadherin-/- ES cells are defective in cell aggregation; this defect can be corrected by transfection with cDNA for either E-cadherin or N-cadherin driven by a constitutive promoter. The presence (or absence) of E-cadherin regulates the expression of the transcription factor T-brachyury, indicating that cadherins play a role in linking cell surface receptors and gene expression. Comparative analysis of the parental and the genetically altered ES cell lines was performed to examine cell differentiation and the capability to form organized tissues. While differentiating E-cadherin-/- ES cells are still able to express various early and late differentiation markers, they show a clear-cut deficiency in forming organized structures. This phenotype can be rescued by constitutive expression of E-cadherin, which results exclusively in formation of epithelia. In contrast, rescue transfectants expressing N-cadherin show no epithelial structures, instead forming neuroepithelium and cartilage. These results provide the first evidence that specific cadherins directly stimulate differentiation into certain types of tissues.


Subject(s)
Cadherins/metabolism , Embryonic and Fetal Development/physiology , Signal Transduction/physiology , T-Box Domain Proteins , Animals , Cadherins/genetics , Cell Aggregation , Cell Differentiation , Cell Line , DNA-Binding Proteins/genetics , Fetal Proteins/genetics , Gene Deletion , Gene Expression , Mice , RNA , Rabbits , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...